Science News
from research organizations

Alternative target for breast cancer drugs

Date:
July 19, 2013
Source:
EMBO - excellence in life sciences
Summary:
Scientists have identified higher levels of a receptor protein found on the surface of human breast tumor cells that may serve as a new drug target for the treatment of breast cancer. The results show that elevated levels of the protein Ret, which is short for “Rearranged during transfection”, are associated with a lower likelihood of survival for breast cancer patients in the years following surgery to remove tumors and cancerous tissue.
Share:
       
FULL STORY

Scientists have identified higher levels of a receptor protein found on the surface of human breast tumour cells that may serve as a new drug target for the treatment of breast cancer. The results, which are published today in EMBO Molecular Medicine, show that elevated levels of the protein Ret, which is short for "Rearranged during transfection," are associated with a lower likelihood of survival for breast cancer patients in the years following surgery to remove tumours and cancerous tissue.

"Our findings suggest that Ret kinase might be an attractive and novel alternative therapeutic target in selected groups of breast cancer patients," remarked Nancy Hynes, Professor at the Friedrich Miescher Institute for Biomedical Research and the University of Basel, Switzerland. "Initial experiments in mice that serve as model organisms for the study of breast cancer have revealed that specific inhibitors significantly block the spread of cancer and decrease the number of metastatic tumours found in the lungs."

The scientists examined tumour tissue microarrays of more than 100 breast cancer patients who had undergone surgery to remove their tumours. Antibodies were used to detect the levels of Ret in the samples. In other experiments, four different cancer cell lines were used and injected into mice to study the effects of Ret inhibitors on the progress and spread of the cancer.

"Our findings demonstrate that blocking Ret kinase not only decreases the growth of tumours but also impacts the potential of the cancer to spread throughout the body," Hynes said.

Targeting receptor tyrosine kinase enzymes with antibodies or small molecular inhibitors is a clinically validated approach for cancer therapy. However, only a subset of patients are eligible for these types of treatments which makes it essential to discover additional inhibitors that could be useful in breast cancer therapy.

Dr. Albana Gattelli was supported by grant KG101234 from Susan G. Komen for the Cure®


Story Source:

The above post is reprinted from materials provided by EMBO - excellence in life sciences. Note: Materials may be edited for content and length.


Journal Reference:

  1. Albana Gattelli, Ivan Nalvarte, Anne Boulay, Tim C. Roloff, Martin Schreiber, Neil Carragher, Kenneth K. Macleod, Michaela Schlederer, Susanne Lienhard, Lukas Kenner, Maria I. Torres-Arzayus, Nancy E. Hynes. Ret inhibition decreases growth and metastatic potential of estrogen receptor positive breast cancer cells. EMBO Molecular Medicine, 2013; DOI: 10.1002/emmm.201302625

Cite This Page:

EMBO - excellence in life sciences. "Alternative target for breast cancer drugs." ScienceDaily. ScienceDaily, 19 July 2013. <www.sciencedaily.com/releases/2013/07/130719083938.htm>.
EMBO - excellence in life sciences. (2013, July 19). Alternative target for breast cancer drugs. ScienceDaily. Retrieved July 31, 2015 from www.sciencedaily.com/releases/2013/07/130719083938.htm
EMBO - excellence in life sciences. "Alternative target for breast cancer drugs." ScienceDaily. www.sciencedaily.com/releases/2013/07/130719083938.htm (accessed July 31, 2015).

Share This Page: